Innovative Biopharma Solutions
In traditional bulk sequencing, data represents average signals from thousands or millions of cells, potentially masking important differences between individual cells.
High-throughput screening (HTS) has transformed drug discovery by enabling researchers to test vast compound libraries in parallel, dramatically speeding up the hunt for new therapeutics.
Spatial biology – encompassing spatial transcriptomics and spatial proteomics – is revolutionizing how scientists study tissues. By preserving the spatial context of gene and protein expression, these techniques enable insights that traditional bulk genomics or single-cell methods cannot achieve.
Single-cell sequencing is transforming life sciences by unlocking cell-by-cell insights previously hidden in bulk population averages. Whether you're uncovering immune cell diversity, profiling tumor heterogeneity, or building multi-omic atlases of complex tissues, the ability to analyze individual cells has become a foundational tool in research and translational medicine.
Spatial biology – incorporating spatial transcriptomics and spatial proteomics – is transforming how scientists understand tissue architecture at the molecular level. By retaining spatial context in gene and protein expression studies, researchers gain insights into tissue heterogeneity, disease microenvironments, and molecular localization that traditional bulk or single-cell methods often miss.
High-throughput screening (HTS) enables researchers to test tens of thousands of compounds in parallel, accelerating the identification of potential therapeutics. Whether targeting enzymes, receptors, or cellular pathways, the success of HTS depends not just on instrumentation — but on carefully selected assay reagents, microplates, and consumables engineered for precision, miniaturization, and automation.
The Role of Buffers in Biopharmaceutical Manufacturing
In biologics production—whether recombinant proteins, monoclonal antibodies, or cell-based therapies—buffer systems play a foundational role across the entire bioprocessing chain
For many CDMOs and cell therapy facilities, buffer prep is a hidden bottleneck. It starts innocently—jugs of sodium phosphate, a few techs, and an SOP written three revisions ago. But fast-forward to GMP scale and audit season, and suddenly, in-house buffer prep becomes a liability.